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Specific Care Question:
For the child with bronchiolitis (> 2 months and < 24 months of age) is high flow nasal cannula (HFNC) therapy as efficacious as
conventional respiratory therapy?
Question Originator:
Kathleen Berg, MD and Amanda Nedved, MD- Bronchiolitis Clinical Practice Guideline Team Leaders
Literature Summary:
Background
The primary treatment for children admitted with bronchiolitis continues to be providing supplemental oxygen, suctioning to remove
secretions, and encouraging feedings (Ralston et al., 2014). Conventionally, low-flow nasal prongs are the method used to deliver
supplemental oxygen patients with bronchiolitis. High flow nasal cannula allows the delivery of a heated, humidified air/oxygen blend at
higher flows, which may improve ventilation. High flow rates of > 1 L/min to 5 L/min for infants and up to 15 L/min in older children
can be administered (Riese, Fierce, Riese, & Alverson, 2015). The High Flow Nasal Cannula Administration Policy became effective at
Children’s Mercy Adele Hall Campus on April 2016 (Children’s Mercy Hospital, 2017). At Children’s Mercy, the goals of HFNC therapy are
(a) stabilization of FiO2 requirement with an increase in PaO2 or SpO2 levels, (b) maintain adequate minute ventilation (VE) with
acceptable PaCO2 levels, (c) reduce the work of breathing, (d) improve lung volume and lungs appearance on chest x-ray, and (e)
improve patient comfort.
Study characteristics
The search for suitable studies was completed on November 2017. Jeff Michael, DO reviewed the 100 titles and abstracts found in the
search and identified 11 articles believed to answer the question. After an in-depth review 4 articles answered the question. Two of the
articles were included in a previous review on this topic, and two are new. Kepreotes et al. (2017), a randomized control trial (RCT),
along with Bressan et al. (2013), a prospective observational pilot study, are added to this synthesis. Since there is only one RCT,
Kepreotes et al. (2017), a meta-analysis was not performed. Bressnan et al (2013 is a prospective cohort study. Other papers include a
non-blinded pilot study (Hilliard et al., 2012), and cohort studies, and one retrospective (Riese et al., 2012).
Key results
Overall the quality of evidence is very low. With the addition of the new articles, there continues to be insufficient evidence to
determine the effectiveness of HFNC for the treatment of bronchiolitis in children < 2 years of age. This concurs with the
recommendations from the AAP (Ralston et al., 2014), the Canadian Pediatric Society (Friedman et al., 2014), and the National
Institute for Health and Care Excellence, Guidelines (NICE, 2015). Further research on the efficacy of HFNC, either in the PICU or on an
inpatient unit is likely to have important influence on our confidence in making a recommendation.
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Summary by Outcome
Treatment Failure. Kepreotes et al., (2017) reported significantly lower odds OR = 0.33, p = .002, 95% CI [0.16,0.67] of treatment
failures (critically abnormal observations that fell within the red zone on age-appropriate Standard Pediatric Observation Charts for
heart rate, respiratory rate, SpO2 (<90%), or respiratory distress score (severe) while on maximum therapy) when treated with HFNC.
Escalation of care. Three studies reported on escalation of care, defined as either transfer to the PICU, or provision of mechanical
ventilation. Kepreotes et al. (2017), reported no difference in the odds of being transferred to the PICU, OR = 1.19, p = .67, 95% CI
[0.52, 2.73]. Likewise, Bressan et al. (2013) reported no transfers to the PICU. Riese, Fierce, Riese, and Alverson (2015) reported no
difference in number of patients intubated or transferred back to the PICU after the implementation of a protocol to administer HFNC on
the general pediatric floors. The latter two studies are non-randomized studies.
Length of stay. Riese et al. (2015) reported significantly, p < .001, shorter median length of stay and median total hospital charges.
However, (Hilliard et al., 2012; Kepreotes et al., 2017) report no difference in the length of stay for those treated with HFNC and those
treated with standard therapy for bronchiolitis.
Search Strategy and Results (see PRISMA diagram):
Searches performed on Nov 17, 2017
PubMed- Search: ("Respiratory Syncytial Virus Infections/therapy"[Mesh] OR "Bronchiolitis/therapy"[Mesh] OR "bronchiolitis") AND
(HFNC[tiab] OR "high-flow nasal cannula" OR "high flow nasal cannula" OR (("Cannula"[Mesh] OR "nasal cannula" OR "nasal cannulae")
AND "Oxygen Inhalation Therapy"[Mesh])) AND (infant OR child OR children OR childhood OR paediatr* OR pediatr*) Filters: From
2013/01/01 to 2017/12/31 70 results
CINAHL: (MH "Bronchiolitis+/TH") OR "bronchiolitis" OR (MH "Respiratory Syncytial Virus Infections/TH") AND (MH "Nasal Cannula") OR
"nasal cannula" OR "nasal cannulae" AND (MH "Oxygen Therapy+") OR (MH "Oxygen Therapy Care (Saba CCC)") "HFNC" OR "high-flow
nasal cannula" OR "high flow nasal cannula" 30 results
Total number and question originator: Bronchiolitis CPG Team
Studies included in this review:
From previous CAT:
Hilliard et al. (2012)
Riese et al. (2015)
New evidence added to update this CAT:
Bressan et al. (2013)
Kepreotes (2017)
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Studies not included in this review with exclusion rationale:
Authors, Year
Beggs et al. (2014)
Chowdhury (2013)
Franklin (2015)
Gomes (2016)
Kelly (2013)
Mayfield (2017)
Milesi (2013)
Seliem (2017)

Reason for exclusion
Systematic review that only includes Hilliard et al. (2012)
Does not answer the question
Protocol
Does not answer the question
Does not answer the question
Case Control study
All subjects treated in the PICU
Does not answer the question

Method Used for Appraisal and Synthesis:
The Cochrane Collaborative computer program, Review Manager (Higgins & Green, 2011)a was used to synthesize the four included studies.
GRADEpro GDT (Guideline Development Tool) is the tool used to create the Summary of Findings Tables for this analysis.
aHiggins,

J. P. T., & Green, S. e. (2011). Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011] (Version 5.1.0
ed.): The Cohcrane Collaboration, 2011.

EBP Scholar’s responsible for analyzing the literature:
Shellie Brandon, LMSW-KS & MO
Jennifer Foley, RT(R)(N), CNMT
David Keeler, RN, BSN, CPN
Helen Murphy, BHS RRT AE-C
Robert Rhodes, MHA, RRT-NPS
EBP team member responsible for reviewing, synthesizing, and developing this document:
Nancy H. Allen, MS, MLS, RD, LD
Date Developed/Updated: January 2018
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Identification

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA)b
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b

Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group
(2009). Preferred Reporting Items for Systematic Reviews and
Meta-Analyses: The PRISMA Statement. PLoS Med 6(7):
e1000097. doi:10.1371/journal.pmed1000097
For more information, visit www.prisma-statement.org.
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Table 1
AGREE Summary for the Ralston et al. (2014) AAP Guideline for Bronchiolitis.
Domain
1 - SCOPE AND PURPOSE

Percent Agreement
100%

2 - STAKEHOLDER INVOLVEMENT

87%

3 - RIGOR OF DEVELOPMENT

96%

4 - CLARITY AND PRESENTIATION

87%

5 - APPLICABILITY

53%

6 - EDITORIAL INDEPENDENCE

96%

Overall Guideline Assessment

90%
Note: Three EBP Scholars completed the AGREE II on this guideline.

cAGREE

II is an international instrument* used to assess the quality and reporting of clinical practice guidelines.

A quality score is calculated for each of the six AGREE II domains (scope and purpose; stakeholder involvement; rigor of development; clarity
of presentation; applicability; editorial independence). A higher domain percent reflects a stronger agreement that the guideline met the
domain criteria. The AGREE II quality score does not judge the evidence used or the strength of the recommendations made by the
guideline, only the process used to develop the guideline (Brouwers, et al., 2010).

*Brouwers, M.C. et al. for the AGREE Next Steps Consortium. (2010) AGREE II: Advancing guideline development, reporting and evaluation in
healthcare. Canadian Medical Association Journal, 182, E839-842. Retrieved from https://www.agreetrust.org/wpcontent/uploads/2017/12/AGREE-II-Users-Manual-and-23-item-Instrument-2009-Update-2017.pdf
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Table 2
Characteristics of Included Studies
Bressan 2013
Methods
Participants

Interventions

Prospective observational pilot study
Setting: Italy, Pediatric tertiary care academic center, Nov 2011-April 2012
Number in study: N = 27
Age: Range = 7 days to 12 months, median = 1.3 months
Gender, male: 51%
Inclusion Criteria:
 Subjects admitted to hospital (General Pediatric Ward)
 First episode of moderate-severe bronchiolitis (Wang score > 5 = moderate, >10 = severe)
 Requiring supplemental O2
 Received HFNC O2 therapy
Exclusion Criteria:
 Recurrent wheezing
 Underlying hemodynamically significant heart disease
 Chronic lung disease
 Neuromuscular disease
 Oxygen therapy at home
 Tracheostomy






Outcomes

Patients were treated with 3% nebulized hypertonic saline when presenting SpO2 was <= to 92%
Nebulized salbutamol was given if audible wheezing was present
In the ED, children with severe bronchiolitis were given 0.25 mg/kg nebulized epinephrine in 3%
hypertonic saline and standard oxygen via nasal cannula, up to 2 liter/minute
HFNC was initiated on the ward as:
o Heated, humidified (3% hypertonic saline) high-flow nasal cannula (HFNC) oxygen therapy
o Flow rate 1-8 liter/minute
o FIO2 titrated to maintain SpO2>/=94%
o Flow rate weaned by 1 liter/minute q 6 hours with SpO2 >/=94 with FiO2 at 25%
o Pt weaned to standard O2 therapy once they remained stable at HFNC=2 liters/min

Respiration Rate (RR)
Sat O2 at
 t-1 hour of HFNC
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Notes

t+1 hours of HFNC
t+3 hours of HFNC

Respiration Rate: median RR (absolute range)
 t-1 hour: 67 (35-90)
 t=1 hour after HFNC initiation: 50 (30-80)
 t=3 hour after HFNC initiation: 54 (38-75)
Oxygen saturation, Room air: % (absolute range)
 t-1 hour: 89 (82-93)
Oxygen saturation, Regular Nasal Cannula: % (absolute range)
 t-1 hour: 96 (90-99)
Oxygen saturation, HFNC: % (absolute range)
 t=1 hour after HFNC initiation: 97 (93-100)
 t=3 hour after HFNC initiation: 98 (94-100)
Escalation of respiratory effort was not the reason for transfer to the PICU.
There was no comparison group, all patients received the HFNC intervention.
Confounding factors were suctioning, provision of salbutamol, or racemic epinephrine prior to admission.

Hilliard et al., 2012
Methods
Participants

Interventions

Prospective, randomized, open pilot study
Number included: N = 19
Gender: not reported
Age: median age 3 months, range [0.3-11.3]
Inclusion criteria: clinical diagnosis of moderately severe bronchiolitis
Exclusion criteria: not reported
Power analysis: not reported
Both groups: Oxygen concentration adjusted to achieve target pulse oximeter oxygen saturation (SpO2) of
92-96%
Treatment group: HFNC, n = 11
Vapotherm 2000i (Vapotherm Inc., Stevensville, Maryland, USA) at 4 liters per minute with 100% oxygen
and increased up to 8 liters per minute if tolerated.
 Continued for at least 24 hours then flow rate decreased sequentially and switched to dry oxygen
once 2 liters per minute.
Control group: oxygen hood : n = 7
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Outcomes

Notes

Bias
Random sequence generation
(selection bias)

Primary outcomes
 SpO2 at 8 hours post randomization
 Length of stay, or time until ready for discharge
This is the only study included in the Beggs et al., (2014) a Cochrane SR/MA. The search strategy included
records published until May 15, 2013.
Scholars'
judgment
Unclear risk

Allocation concealment
(selection bias)

High risk

Blinding of participants and
personnel (performance bias)

High risk

Blinding of outcome
assessment (detection bias)

High risk

Incomplete outcome data
(attrition bias)

Low risk

Selective reporting (reporting
bias)

Low risk

Other bias

High risk

Support for judgment
Method to generate the sequence was not described
Authors did not disclose
There was no attempt made to blind
There was no attempt made to blind
All subjects completed the study
Not evident
The weaning protocols for the two treatments were different. The HFNC protocol had a
slower wean than did the head box oxygen protocol.

Kelly 2013
Methods
Participants

Retrospective Cohort review
Participants: All children 24 months or younger evaluated in 2 pediatric emergency departments between
June 2011 and September 2012
Setting: Two tertiary care pediatric emergency departments
Number enrolled: N = 498
Number completed: N = 306
Gender, males (%):
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Non-intubated: n = 272 (59.6)
Intubated: n = 26 (61.9)
Age, years (mean):
 Non-intubated: n = 10.7 (6.1)
 Intubated: n = 10.1 (6.6)
Inclusion Criteria:
 All children 24 months or younger who received HFNC within 24 hours of initial triage in the
emergency department
Exclusion Criteria:
 Trauma or non-accidental trauma
 Preexisting tracheostomy
 DNR
 Intubation occurring prior antecedent HFNC trial
 Intubations occurring for reasons other than respiratory failure
Covariates Identified:
 Initial RR > 90th percentile
 Initial Pco2 > 50 mm Hg
 Initial PH < 7.3
 Previous intubation for respiratory failure
 RSV positive
 Corrected age <1 month
 Diagnosis of acute bronchiolitis
Interventions

HFNC initiated in the emergency department as first therapy in children 24 months and younger within the
first 24 hours of initial triage. Most started treatment in the ED or PICU; a minority started on inpatient
units (location of treatment start not reported)

Outcomes

Investigate the patient characteristics that predict success or failure of HFNC in infants and young children
presenting to the pediatric emergency department
Therapy failure was defined as clinical deterioration in respiratory status or respiratory failure requiring
intubation within 48 hours from the time of HFNC initiation.
The decision to intubate was independent at the discretion of the ED or PICU physicians.

Notes

Results:
 690 charts of patients who received HFNC were reviewed
 498 cases met all inclusion criteria
 42 cases (8%) required intubation
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456 cases were successful with HFNC. Of these cases, the most common final diagnosis was acute
bronchiolitis
192 cases were excluded from the regression model due to missing data.
Four variables were strongly associated with increased risk for intubation following HFNC trial
model:
1. Triage RR greater than 90th percentile for age, OR = 2.11, p =.047, 95% CI [1.01, 4.43]
2. Initial venous PCO2 greater than 50 mm Hg, OR = 2.51, p = .037, 95% CI [1.06, 5.98]
3. Initial venous PH less than 7.30, OR = 2.53, p =.026, 95% CI [1.12, 5.74]
One variable was found to be protective with respect to intubation following HFNC trial model:
1. Diagnosis of acute bronchiolitis OR = 0.40, p =.041, 95% CI [0.17,0.96]

Kepreotes et al., 2017
Methods
Participants

Randomized control trial
Setting: Emergency department at John Hunter Hospital and medical unit of John Hunter Children's
Hospital in New South Wales (NSW), Australia
Randomized into study: N = 202
 Group 1: High-flow warm humidified oxygen (HFWHO) n = 101
 Group 2: Standard therapy n = 101
Completed Study: N = 170
 Group 1: n = 90 followed up at 30 days post-discharge
 Group 2: n = 80 followed up at 30 days post-discharge
Gender, males:
 Group 1: n = 63%
 Group 2: n = 74%
Age, months [median] (SD):
 Group 1: 6 months, range [3-10 months]
 Group 2: 5 months, range [3-10 months]
Inclusion Criteria:
 Children ages less than 24 months presenting to the ED or admitted to the ward if they had a
clinical diagnosis of bronchiolitis that was assessed as being of moderate severity using the NSW
Health clinical practice guideline and required supplemental oxygen
 Infants with chronic neonatal lung disease on home oxygen could be included, but they were
weaned to their home oxygen rate rather than to room air
Exclusion Criteria:

If you have questions regarding this Specific Care Question – please contact Kathleen Berg, MD, Amanda Nedved, MD, or Jeff Michael, DO
10

Office of Evidence Based Practice (EBP) – Critically Appraised Topic: High Flow Nasal Cannula for
Bronchiolitis Final 2018


Children with mild bronchiolitis not requiring oxygen (although could be enrolled if condition
deteriorated)
 Children with severe or life-threatening bronchiolitis as defined by NSW Health including any of the
following: witnessed apnea, severe tachypnea or bradypnea; moderate-severe grunting, cyanosis,
or pallor
 SpO2 < 90% on room air or less than 92% on 2 L/minute oxygen via nasal cannula
 Marked tachycardia or bradycardia;
 Children admitted to the ward after ICU management
 Children transferred from other facilities if they had received supplemental oxygen prior to arrival
 Known diagnosis of asthma
 Presence of pneumothorax or nasal trauma
 Children with severe or life-threatening bronchiolitis were excluded because low-flow oxygen is not
part of standard care for these patients
Power Analysis: Total study sample size of 202 children required to provide 80% power
Interventions




Outcomes

Group 1: High-flow warm humidified oxygen (HFWHO) delivered via age-appropriate Optiflow Junior
nasal cannula and the MR850 humidifier using a maximum flow of 1 L/kg per min to a limit of 20
L/min using 1:1 air-oxygen ratio
Group 2: Cold wall oxygen 100% via infant nasal cannula at low-flow to a maximum of 2 L/min

Primary outcome(s):
 Time to weaning off oxygen which is defined as the time from randomization to the first sustained
room-air observation after oxygen, -- i.e., the first observation recorded in room air with no further
need for subsequent supplemental oxygen
Secondary outcome(s)
 Length of hospital stay, baseline-adjusted heart rate and respiratory rate at 4 h and 24 h, parentreported outcomes collected through the follow-up phone interviews
Safety outcome(s): Time from randomization to treatment failure, proportion of serious adverse events,
and transfer to ICU
Treatment failure is defined as critically abnormal observations that fell within the red zone on ageappropriate Standard Pediatric Observation Charts for heart rate, respiratory rate, SpO2 (<90%), or
respiratory distress score (severe) while on maximum therapy.

Notes

Time to oxygen weaning:
 HFWHO—Median 20 hours [95% CI, 17-34] vs Standard therapy—Median 24 hours [95% CI,
18,28], p = 0.61
o Note the difference in hours on therapy HFNC vs Standard is 4 hours
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- Unable to make a table because the study reported median time on therapy, not mean
time on therapy
- Charts were made for safety outcomes, treatment failure and PICU admission
Risk of bias table
Bias
Random sequence generation
(selection bias)

Scholar’s
judgement

Support for judgement

Low risk

Randomly allocated the patients using a block size of four and stratification for gestational
age at birth.

Low risk

Concealed allocation, evidenced by group assignment kept in opaque, sealed envelopes.
Children were randomly assigned according to gestational age to either standard therapy or
HFWHO by a member of the research team or by the medical registrar.

Low risk

Masking of the allocation was not possible due to obvious visual differences between the two
modes of oxygen delivery; but with the objectivity of the measured outcomes the review
authors judge that the outcome is not likely to be influenced by lack of participant and
personnel blinding

Low risk

The study did not address this outcome; but with the objectivity of the measured outcomes
the review authors judge that the outcome is not likely to be influenced by lack of outcome
assessor blinding

Incomplete outcome data
(attrition bias)

Low risk

No missing outcome data; authors provided ITT and per protocol analysis

Selective reporting (reporting
bias)

Low risk

Pre-specified outcomes are reported

Other bias

Low risk

The study appears to be free of other sources of bias.

Allocation concealment
(selection bias)
Blinding of participants and
personnel (performance bias)

Blinding of outcome
assessment (detection bias)

Riese et al, 2015
Methods
Participants

Retrospective, nonrandomized, pre-intervention vs post-intervention by chart review
Setting: USA, large urban children's hospital
Number Randomized: NOT randomized, but included total group size N= 290
1. Infants <24 months of age
2. Admitted to the PICU between April 1, 2010 and March 31, 2014
3. Diagnosis of bronchiolitis by ICD9
1. 466.19 (not RSV bronchiolitis)
2. 466.11 (RSV bronchiolitis)
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3. 786.03 (apnea)
4. 465.9 (acute upper respiratory infection)
5. V73.99 (unspecified viral illness)
4. n = 120 (24 months prior to protocol implementation)
5. n = 170 (24 months post protocol implementation)
Inclusion criteria:
 initially admitted to the PICU and received HFNC
Exclusion criteria:
 Greater than 24 months of age (to reduce inclusion of non-bronchiolitis acute respiratory infections)
 Hospitalizations greater than 21 days (to reduce inclusion of more complex cases)
 Infant's with gestation of less than 37 weeks
 Specific diagnosis of chronic lung disease
 Asthma
 Chromosomal abnormalities
 Heart disease
 Neurological disease
Interventions
Outcomes

Notes

Application of HFNC by a prescribed HFNC protocol
Primary:
 Length of stay after initiation of HFNC protocol
Secondary:
 Total hospital charges
 Intubation rates
 30-day readmission
HFNC defined as a flow >2 LPM and using a heated humidification device
Intervention Outcome Measures (Median and IQR interquartile range)
Median Total LOS (days)
Before: 4 (IQR 3-5)
After: 3 (IQR 2-4)
p < .001
Median Total Hospital Charges
Before: $12,257 (IQR 8,365-17,226)
After: $9,337 (IQR 6,882-12,624)
p < .001
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Intubation (Adverse Outcome)
Before: 9/120 (7.5%)
After: 11/170 (6.5%)
p =. 73
30-d Readmission (Adverse Outcome)
Before: 11/120 (9.2%)
After: 13/170 (7.7%)
p = .64
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